5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis

Leukemia Research

Volumn 34, Issue 3, 2010, Pages 364-372

  Valdez, Benigno C ^a   Li, Yang ^a   Murray, David ^b   Corn, Paul ^a   Champlin, Richard E ^a   Andersson, Borje S ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b CROSS CANCER INSTITUTE   (Canada)

Author keywords

5 Aza 2 deoxycytidine; Apoptosis; Busulfan; Cell cycle signaling; DNA methylation; Drug resistance; Myeloid leukemia

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BUSULFAN; CASPASE 3; CASPASE 8; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PIFITHRIN ALPHA; PROTEIN BNIP3; PROTEIN CIAP1; PROTEIN CIAP2; PROTEIN P53; PUMA PROTEIN; SHORT HAIRPIN RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL STRAIN K 562; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DNA METHYLATION; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EPIGENETICS; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; SIGNAL TRANSDUCTION; UPREGULATION;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AZACITIDINE; BLOTTING, WESTERN; BUSULFAN; CELL LINE, TUMOR; CELL SEPARATION; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, CDC; HUMANS; IN SITU NICK-END LABELING; LEUKEMIA, MYELOID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 77649186646     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.08.014     Document Type: Article

References (47)

1. Nyce J.W. Drug-induced DNA hypermethylation: a potential mediator of acquired drug resistance during cancer chemotherapy. Mutat Res 1997, 386:153-161.
2. Biedler J.L. Genetic aspects of multidrug resistance. Cancer 1992, 70:1799-1809.
3. Ramachandran C., Melnick S.J. Multidrug resistance in human tumors-molecular diagnosis and clinical significance. Mol Diagn 1999, 4:81-94.
4. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. New Eng J Med 2003, 349:2042-2054.
5. Teodoridis J.M., Strathdee G., Brown R. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. Drug Resist Update 2004, 7:267-278.
6. Yoo C.B., Jones P.A. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006, 5:37-50.
7. Zhu W.G., Dai Z., Ding H., et al. Increased expression of unmethylated CDKN2D by 5-aza-2′-deoxycytidine in human lung cancer cells. Oncogene 2001, 20:7787-7796.
8. Schmelz K., Sattler N., Wagner M., Lubbert M., Dorken B., Tamm I. Induction of gene expression by 5-aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms. Leukemia 2005, 19:103-111.
9. Issa J.P., Garcia-Manero G., Giles F.J., et al. Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (Decitabine) in hematopoietic malignancies. Blood 2004, 103:1635-1640.
10. Plumb J.A., Strathdee G., Sludden J., Kaye S.B., Brown R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 2000, 60:6039-6044.
11. Gore S.D. Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies. Nat Clin Pract Oncol 2005, (Suppl.):S30-S35.
12. Garcia-Manero G., Kantarjian H.M., Sanchez-Gonzalez B., et al. Phase I/II study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006, 108:3271-3279.
13. Jabbour E., Issa J.-P., Garcia-Manero G., Kantarjian H. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer 2008, 112:2341-2351.
14. Valdez B.C., Murray D., Ramdas L., et al. Altered gene expression in busulfan-resistant human myeloid leukemia. Leuk Res 2008, 32:1684-1697.
15. Lozzio C.B., Lozzio B.B. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975, 45:321-334.
16. Kojima K., Shimanuki M., Shikami M., et al. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia 2008, 22:1728-1736.
17. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
18. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
19. Gavrieli Y., Sherman Y., Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992, 119:493-501.
20. WAF1 and the G2/M phase via the p38 MAP kinase pathway. Leuk Res 2003, 27:999-1007.
21. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996, 93:9821-9826.
22. Rhee I., Bachman K.E., Park B.H., et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002, 416:552-556.
23. Santi D.V., Norment A., Garrett C.E. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci USA 1984, 81:6993-6997.
24. Weisenberger D.J., Velicescu M., Cheng J.C., Gonzales F.A., Liang G., Jones P.A. Role of the DNA methyltransferase variant DNMT3b3 in DNA methylation. Mol Cancer Res 2004, 2:62-72.
25. Okano M., Bell D.W., Haber D.A., Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999, 99:247-257.
26. N2 DNA-alkylating agent-induced phosphorylation of p53 and activation of p21 gene expression. Mutat Res 2002, 500:17-30.
27. WAF1/CIP1 induction by 5-azacytosine nucleosides requires DNA damage. Oncogene 2008, 7:3615-3623.
28. Bunz F., Dutriaux A., Lengauer C., et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282:1497-1501.
29. Kim M.J., Lee J.Y., Lee S.J. Transient suppression of nuclear Cdc2 activity in response to ionizing radiation. Oncol Rep 2008, 19:1323-1329.
30. Krek W., Nigg E.A. Mutations of p34cdc2 phosphorylation sites induce premature mitotic events in HeLa cells: evidence for a double block to p34cdc2 kinase activation in vertebrates. EMBO J 1991, 10:3331-3341.
31. Liston P., Fong W.G., Kelly N.L., et al. Identification of XAF1 as an antagonist of XIAP anti-caspase activity. Nat Cell Biol 2001, 3:128-133.
32. Wilkinson J.C., Wilkinson A.S., Scott F.L., Csomos R.A., Salvesen G.S., Duckett C.S. Neutralization of Smac/Diablo by inhibitors of apoptosis (IAPs). A caspase-independent mechanism for apoptotic inhibition. J Biol Chem 2004, 279:51082-51090.
33. Vousden K.H., Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002, 2:594-605.
34. Abe T., Toyota M., Suzuki H., et al. Upregulation of BNIP3 by 5-aza-2′-deoxycytidine sensitizes pancreatic cancer cells to hypoxia-mediated cell death. J Gastroenterol 2005, 40:504-510.
35. Bromberg J.F., Wrzeszczynska M.H., Devgan G., et al. Stat3 as an oncogene. Cell 1999, 98:295-303.
36. Kaufmann W.K., Paules R.S. DNA damage and cell cycle checkpoints. FASEB J 1996, 10:238-247.
37. Karlsson-Rosenthal C., Millar J.B. Cdc25: mechanisms of checkpoint inhibition and recovery. Trends Cell Biol 2006, 16:285-292.
38. Waldman T., Kinzler K.W., Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995, 55:5187-5190.
39. Agarwal M.L., Agarwal A., Taylor W.R. Stark GR. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 1995, 92:8493-8497.
40. Milligan A., Gabrielli B.G., Clark J.M., Hayward N.K., Ellem K.A. Involvement of p16CDKN2A in cell cycle delays after low dose UV irradiation. Mutat Res 1998, 422:43-53.
41. Chiu C.C., Li C.H., Ung M.W., Fuh T.S., Chen W.L., Fang K. Etoposide (VP-16) elicits apoptosis following prolonged G2-M cell arrest in p53-mutated human non-small cell lung cancer cells. Cancer Lett 2005, 223:249-528.
42. Iwamoto T., Hiraku Y., Oikawa S., Mizutani H., Kojima M., Kawanishi S. DNA intrastrand cross-link at the 5′-GA-3′ sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci 2004, 95:454-458.
43. Sengupta S., Harris C.C. p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 2005, 6:44-55.
44. Ricci J.E., Gottlieb R.A., Green D.R. Caspase-mediated loss of mitochondrial function and generation of reactive oxygen species during apoptosis. J Cell Biol 2003, 160:65-75.
45. Lakhani S.A., Masud A., Kuida K., et al. Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science 2006, 311:847-851.
46. Lyons J., Bayar E., Fine G., et al. Decitabine: Development of a DNA methyltransferase inhibitor for hematological malignancies. Curr Opin Inv Drugs 2003, 4:1442-1450.
47. Ciurea S.O., Andersson B.S. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Tranplant 2009, 15:523-536.